News | July 26, 2024
Piramal Pharma Q1 FY25 net loss narrows
EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24
EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24
The Profit After Tax (PAT) for Q4 FY24 at Rs 36.40 crore, compared to Rs 38.23 crore in Q4 FY23
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Keimed is a leading wholesale pharma distribution with industry leading operating metrics
The disbursement will bolster the company's manufactun'ng capabjljties and foster product diversification, including complex generics
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
The company has secured two orders for male condoms from CMSS worth Rs. 9.65 crores and Rs. 6.58 crores respectively
Ami Organics recently announced contract with global MNC for manufacturing of electrolyte for battery cells
JB Chemicals will pay Rs 125 crore to Novartis to license the same drug portfolio for the Indian market
Subscribe To Our Newsletter & Stay Updated
